Summary
Abbott Laboratories (ABT) has filed an 8-K report on January 21, 2026, to announce its fourth quarter and full-year 2025 financial results. The report highlights that the company's earnings release, furnished as an exhibit, will present both GAAP and non-GAAP financial measures. Investors should pay close attention to these non-GAAP figures as Abbott's management utilizes them to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, legal reserves, and intangible amortization. The company emphasizes that these non-GAAP measures are intended to offer investors greater visibility into the underlying business performance by adjusting for factors that management considers unusual or unpredictable. While these adjustments aim to facilitate better evaluation of operational trends, investors are advised to consider these non-GAAP measures alongside, and not as a substitute for, the GAAP financial measures. The filing also includes the press release and an interactive data file for enhanced analysis.
Key Highlights
- 1Abbott Laboratories reported fourth quarter and full-year 2025 financial results via an 8-K filing.
- 2The company will present both GAAP and non-GAAP financial measures in its earnings release.
- 3Non-GAAP measures are provided to offer insights into ongoing operational performance.
- 4Adjustments in non-GAAP measures include acquisition costs, restructuring actions, legal reserves, and intangible amortization.
- 5Management believes non-GAAP measures allow for better evaluation of underlying business performance.
- 6Investors are advised to consider non-GAAP measures in conjunction with, not as a substitute for, GAAP measures.
- 7The filing includes the earnings press release and an interactive data file.